<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076140</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0222</org_study_id>
    <nct_id>NCT01076140</nct_id>
  </id_info>
  <brief_title>Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab</brief_title>
  <official_title>Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to directly compare the blood pressure (hypertension) reduction&#xD;
      effects of lisinopril and nebivolol in patients who develop new onset or worsening&#xD;
      hypertension while treated with bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled&#xD;
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study will be changes in sitting systolic and diastolic blood pressure at the crossover and final visits.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint of the study will be changes in heart rate at the end of the crossover and final visits.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will be treated with both nebivolol or lisinopril for a period of 4 weeks, and then crossover to the opposite medication for an additional 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks</description>
    <arm_group_label>Lisinopril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients currently treated at the University of Mississippi Medical Center Oncology&#xD;
             Clinic&#xD;
&#xD;
          -  Patient is being treated with bevacizumab either alone or in combination with other&#xD;
             agents for cancer&#xD;
&#xD;
          -  Patient blood pressure is &gt;140 mmHg (systolic) or &gt; 90 mmHg (diastolic), either&#xD;
             treated or untreated with medications for hypertension&#xD;
&#xD;
          -  Patients may be currently on medications for hypertension (other than Beta blocker,&#xD;
             ACEI, or ARB); these will be continued at the same dose throughout the study&#xD;
&#xD;
          -  Patients should be &gt; 18 years of age&#xD;
&#xD;
          -  Patients receiving bevacizumab therapy approximately every 2 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of ACEI or ARB induced angioedema or idiopathic/hereditary angioedema&#xD;
&#xD;
          -  Patient currently treated with a Beta blocker, ACEI, or ARB or have a history of&#xD;
             intolerance to a medication in any of these classes&#xD;
&#xD;
          -  Hyperkalemia, defined as a potassium value of &gt;5 mEq/L&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Severe renal impairment (eGFR &lt;30 mL/min)&#xD;
&#xD;
          -  Moderate hepatic impairment as identified by physician&#xD;
&#xD;
          -  Currently taking CYP2D6 inducers (rifampin, carbamazepine or dexamethasone) or&#xD;
             inhibitors (bupropion, fluoxetine, paroxetine, duloxetine, etc.)&#xD;
&#xD;
          -  History of clinically significant EKG abnormality which would contraindicate beta&#xD;
             blocker use&#xD;
&#xD;
          -  Recent stroke (&lt;6 months)&#xD;
&#xD;
          -  Recent myocardial infarction (&lt;6 months)&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Severe asthma or COPD&#xD;
&#xD;
          -  Diagnosed obstructive sleep apnea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Zachery Somers</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>Hypertension as a result of bevacizumab therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

